News and Events

News

All categories

Earnings

Press Release

All years

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13

April 9, 2021

Affimed to Report Full Year 2020 Financial Results & Corporate Update on April 15, 2021

April 8, 2021

Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors

March 31, 2021

Affimed Announces Presentations at the AACR Annual Meeting 2021

March 10, 2021

Affimed Announces Continuation of REDIRECT, a Registration-directed Study of AFM13 in PTCL, after Positive Preplanned Interim Futility Analysis

March 10, 2021

Affimed Announces Collaboration with Roche to Study AFM24 in Combination with PD-L1 Checkpoint Inhibitor in EGFR Expressing Solid Tumors

February 3, 2021

Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 15, 2021

Affimed Announces Pricing of $100,000,000 Public Offering of Common Shares

January 13, 2021

Affimed Announces Proposed Public Offering of Common Shares

January 12, 2021

Affimed to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 11, 2021

Events

All

Scientific

Investors

There are no events planned at the moment.

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13

Affimed to Report Full Year 2020 Financial Results & Corporate Update on April 15, 2021

Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors

Affimed Announces Presentations at the AACR Annual Meeting 2021

Affimed Announces Continuation of REDIRECT, a Registration-directed Study of AFM13 in PTCL, after Positive Preplanned Interim Futility Analysis

Affimed Announces Collaboration with Roche to Study AFM24 in Combination with PD-L1 Checkpoint Inhibitor in EGFR Expressing Solid Tumors

Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Affimed Announces Pricing of $100,000,000 Public Offering of Common Shares

Affimed Announces Proposed Public Offering of Common Shares

Affimed to Present at the 39th Annual J.P. Morgan Healthcare Conference

Events